STEM CELL'S STROKE DRUG MOVES INTO PHASE IIA

Stem Cell Therapeutics has reported that the FDA has given approval for the Phase IIa trial protocol for its stroke drug, NTx-265.

The trial, which is slated to enroll 12 subjects, will begin in the near future at the University of California at Irvine. In the trial, NTx-265 will be administered 24 to 48 hours after the onset of stroke. The company said it expects to complete study enrollment approximately one year after the trial starts.